Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543268 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
A Phase 3 study, sponsored by Crucell Holland.
- Completed
- Registry status
- Phase 3
- Development phase
- 329
- Enrollment target
NCT02543268: Completed Phase 3 study, sponsored by Crucell Holland.
NCT02543268 is a Phase 3 study that has completed, run by Crucell Holland. The registered enrollment target is 329 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02543268, a Phase 3 study, has completed, sponsored by Crucell Holland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 329 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the humoral immune response induced by 3 different batches of Ad26.ZEBOV as measured by enzyme - linked immunosorbent assay (ELISA) against the Ebola virus (EBOV) GP (Glycoprotein) at 56 days post prime.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MVA-BN-Filo
- BIOLOGICAL Ad26.ZEBOV-Batch #1
- BIOLOGICAL Ad26.ZEBOV-Batch #2
- BIOLOGICAL Ad26.ZEBOV-Batch #3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2015-09-21 |
| Est. Completion | 2016-07-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02543268
The ClinicalTrials.gov registry entry for NCT02543268 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crucell Holland, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02543268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02543268 about?
NCT02543268 is a clinical study titled "A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants". The purpose of this study is to compare the humoral immune response induced by 3 different batches of Ad26.ZEBOV as measured by enzyme - linked immunosorbent assay (ELISA) against the Ebola virus (EBOV) GP (Glycoprotein) at 56 days post prime.
What is the current status of trial NCT02543268?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 329 participants. The study started on 2015-09-21. Estimated completion is 2016-07-20.
What interventions are being tested in trial NCT02543268?
The interventions under investigation include: Placebo (BIOLOGICAL), MVA-BN-Filo (BIOLOGICAL), Ad26.ZEBOV-Batch #1 (BIOLOGICAL), Ad26.ZEBOV-Batch #2 (BIOLOGICAL), Ad26.ZEBOV-Batch #3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02543268?
This trial is sponsored by Crucell Holland, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.